The role of sTILs in this scenario has been studied in the ShortHER trial, which randomly assigned 1253 individuals diagnosed with early HER2+ BC to a combination of anthracycline and taxane-based ChT along with one year (long arm) or nine weeks (short arm) of trastuzumab [33]. The gene discussed is ERBB2; the disease is breast cancer.